Risk Factors for Additional Postoperative Adjuvant Therapy in Patients with Locally Advanced Cervical Cancer and Construction of a Risk Model

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2023 Jan 11

PMID 36628195

Authors

Na Li

Hanbing Wang

Xuemei Gao

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the influencing factors of postoperative adjuvant therapy for stage IB1-IIA2 cervical cancer, and establish a nomogram model to predict the risk of postoperative adjuvant therapy for locally advanced cervical cancer (LACC).

Methods: A retrospective analysis was conducted on 144 patients with stage IB1-IIA2 cervical squamous cell carcinoma treated in Wuhan No.1 Hospital from June 2015 to January 2017, and their clinical data were analyzed. The clinical application value of the nomogram risk model was evaluated by receiver operating characteristic curve (ROC).

Results: Through logistic regression analysis, we found that squamous cell carcinoma antigen (SCC-Ag), International Federation of Gynecology and Obstetrics (FIGO) stage ≥ IIA1, and laparoscopic surgery were independent influencing factors for additional adjuvant therapy after laparoscopic surgery. The nomogram model for predicting the risk of postoperative adjuvant therapy for cervical cancer constructed according to the selected variables had good predictive performance (with C-index of 0.798) and conformity. The area under the curve of established model in predicting 1-, 3- and 5-year survival time was 0.730, 0.810 and 0.830, respectively, indicating that the model has good performance.

Conclusion: History of diabetes, tumor size, FIGO stage ≥ IIA1, and SCC-Ag >1.5 are independent influencing factors for additional adjuvant therapy after laparoscopic surgery of LACC patients. In addition, the constructed risk model is effective in predicting the postoperative risk of additional adjuvant therapy, which is expected to provide a reference for clinical treatment selection.

References

Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S . Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018; 36(16):1548-1555. DOI: 10.1200/JCO.2017.75.9985. View

Liu T, Li R, Huo C, Li J, Yao J, Ji X . Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis. Front Cell Dev Biol. 2021; 9:682002. PMC: 8366777. DOI: 10.3389/fcell.2021.682002. View

Stolnicu S, Hoang L, Soslow R . Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch. 2019; 475(5):537-549. PMC: 6864265. DOI: 10.1007/s00428-019-02601-0. View

Stumbar S, Stevens M, Feld Z . Cervical Cancer and Its Precursors: A Preventative Approach to Screening, Diagnosis, and Management. Prim Care. 2019; 46(1):117-134. DOI: 10.1016/j.pop.2018.10.011. View

Gadducci A, Cosio S . Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research. Anticancer Res. 2020; 40(9):4819-4828. DOI: 10.21873/anticanres.14485. View

Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G . Locally advanced cervical cancer: A study of 5-year outcomes. Indian J Cancer. 2018; 55(1):45-49. DOI: 10.4103/ijc.IJC_428_17. View

Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T . Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013; 108(10):1957-63. PMC: 3671094. DOI: 10.1038/bjc.2013.179. View

Polterauer S, Grimm C, Hofstetter G, Concin N, Natter C, Sturdza A . Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer. 2012; 107(6):918-24. PMC: 3464766. DOI: 10.1038/bjc.2012.340. View

Shou H, Yasuo Y, Yuan S, Lou H, Ni J . Association of pretreatment SUV of cervix and SCC-antigen with FIGO2018 stage in Stage IIB-IVB squamous cervical cancer and relationship to prognosis. Int J Gynaecol Obstet. 2020; 152(1):112-117. DOI: 10.1002/ijgo.13465. View

10.

Koh W, Abu-Rustum N, Bean S, Bradley K, Campos S, Cho K . Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(1):64-84. DOI: 10.6004/jnccn.2019.0001. View

11.

Xu Y, Wang Z, Liang X, Wang Y, Wang J . [Comparative analysis of the prognosis of patients with locally advanced cervical cancer undergoing laparoscopic or abdominal surgery]. Zhonghua Fu Chan Ke Za Zhi. 2020; 55(9):609-616. DOI: 10.3760/cma.j.cn112141-20200727-00612. View

12.

Saleh M, Virarkar M, Javadi S, Elsherif S, de Castro Faria S, Bhosale P . Cervical Cancer: 2018 Revised International Federation of Gynecology and Obstetrics Staging System and the Role of Imaging. AJR Am J Roentgenol. 2020; 214(5):1182-1195. DOI: 10.2214/AJR.19.21819. View

13.

Vergote I, Magrina J, Zanagnolo V, Magtibay P, Butler K, Gil-Moreno A . The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. J Minim Invasive Gynecol. 2019; 27(2):462-463. DOI: 10.1016/j.jmig.2019.09.767. View

14.

Sturdza A, Potter R, Kossmeier M, Kirchheiner K, Mahantshetty U, Haie-Meder C . Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study. Int J Radiat Oncol Biol Phys. 2021; 111(1):168-177. DOI: 10.1016/j.ijrobp.2021.04.022. View

15.

Zou T, Zheng C, Zhang Z, Yu L, Fu C . Neoadjuvant chemotherapy efficacy and prognostic factors in 187 cervical cancer patients with IB2 and IIA2 stage. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020; 45(3):297-304. DOI: 10.11817/j.issn.1672-7347.2020.190105. View

16.

Ramirez P, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R . Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018; 379(20):1895-1904. DOI: 10.1056/NEJMoa1806395. View

17.

Hu Z, Ma D . The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med. 2018; 7(10):5217-5236. PMC: 6198240. DOI: 10.1002/cam4.1501. View

18.

Mohanty G, Ghosh S . Risk factors for cancer of cervix, status of screening and methods for its detection. Arch Gynecol Obstet. 2014; 291(2):247-9. DOI: 10.1007/s00404-014-3492-1. View

19.

Suh S, Kim K . Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment. Diabetes Metab J. 2020; 43(6):733-743. PMC: 6943263. DOI: 10.4093/dmj.2019.0177. View

20.

Fu J, Wang W, Wang Y, Liu C, Wang P . The role of squamous cell carcinoma antigen (SCC Ag) in outcome prediction after concurrent chemoradiotherapy and treatment decisions for patients with cervical cancer. Radiat Oncol. 2019; 14(1):146. PMC: 6694518. DOI: 10.1186/s13014-019-1355-4. View